Sanofi Reports Results of Fitusiran in P-III (ATLAS-PPX) Study for the Treatment of Hemophilia A or B
- The P-III (ATLAS-PPX) study evaluated fitusiran (80 mg, qm) in 80 adults & adolescents aged ≥12yrs. with sev. hemophilia A or B with/out inhibitors who were prior treated with a prior factor or BPA prophylaxis
- The study met its 1EPs and showed a 61% reduction in bleeding episodes over 16.9% with prior factor or BPA prophylaxis; patients experienced zero treated bleeds (63.1% vs 16.9%); m-ABR for treated bleeds was 0.0 with/out inhibitors vs 6.5 and 4.4 for patients with/out inhibitors, respectively on prior prophylaxis.
- 67 patients were exposed to one dose of fitusiran. The results were consistent with the prior identified risk of fitusiran, 2 patients (3.0%) reported suspected or confirmed thromboembolic events
Ref: GlobalNewswire | Image: Sanofi
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.